BioCryst Pharmaceuticals, Inc.

+$0.59 (+5.8%)
Closing price June 24, 2022
Idera Pharmaceuticals shares crumbled on Wednesday after BioCryst Pharmaceuticals announced that it terminated the merger agreement.
The top analyst upgrades, downgrades and other research calls from Friday include Bookings Holdings, Dollar General, KLA-Tencor, Micron Technology, Nike and Red Hat.
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
The include BioCryst Pharmaceuticals, Exxon Mobil, Fiat Chrysler Automobiles, Hewlett Packard Enterprise, IAMGOLD, Mallinckrodt and Rockwell Collins.
BioCryst Pharmaceuticals saw its shares make a handy gain on early Tuesday after it released the final results from its mid-stage clinical trial in hereditary angioedema.
The top analyst upgrades, downgrades and initiations seen on Thursday include BioCryst Pharmaceuticals, Cisco Systems, Groupon, SunPower, Tesla and Wells Fargo.
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
These biotech companies 24/7 Wall St. has picked stood out from the rest with big moves over the course of last week.
BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
For the third straight week, insider selling has been nonexistent, while the insider buyers have taken advantage of the market sell-off.
Jefferies is out with its first group of growth stocks to buy this year, and the list has not only some timely picks, but companies that have been knocked to levels that are providing some of the...
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk...